Download Proposal to list ABM Pharma Limited`s brand of cephalexin 500 mg

30 April 2010
Proposal to list ABM Pharma Limited’s brand of cephalexin 500 mg
capsules
PHARMAC is seeking feedback on a proposal to fund ABM Pharma Limited’s brand of
cephalexin monohydrate 500 mg capsules (Cephalexin ABM) from 1 September 2010.
In summary, this proposal would result in:
§
The Cephalexin ABM brand of cephalexin monohydrate 500 mg capsules being
listed in section B and Part II of Section H of the of the Pharmaceutical Schedule
from 1 September 2010; and
§
Subsidy and delisting protection for Cephalexin ABM until 1 July 2013.
Feedback sought
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in
writing by Friday, 14 May 2010 to:
Greg Williams
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143
Email: [email protected]
Fax:
04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or
Chief Executive acting under delegated authority) prior to making a decision on this
proposal.
Details of the proposal
PHARMAC and AMB Pharma Limited have entered into a provisional agreement relating to
the supply of cephalexin monohydrate 500 mg capsules (Cephalexin ABM).
Cephalexin ABM would be listed, in the Infections – Agents for Systemic Use therapeutic
group, in Section B and Part II of Section H of the Pharmaceutical Schedule from 1
September 2010 at the following prices and subsidies (ex manufacturer and exclusive of
GST):
Chemical
Presentation
Brand
Pack size
Price and subsidy
Cephalexin
monohydrate
Capsules, 500 mg
Cephalexin ABM
20
$8.90
Cephalexin ABM would have subsidy and delisting protection until 1 July 2013.
A350455
Page 1 of 2
Background
PHARMAC currently funds cephalexin granules for oral liquid 125 mg per 5 ml and 250 mg
per 5 ml without restriction. This proposal would secure supply of a cephalexin capsule until
at least 1 July 2013. The indicated daily adult dose of cephalexin is between one and four
grams daily. Whilst this dosage can be provided by the oral liquid the capsule formulation
would be a more acceptable dosage form.
Cephalexin is a first generation oral cephalosporin indicated for the treatment of the
following infections when caused by susceptible strains of microorganisms:
·
·
·
·
·
·
·
Bacterial sinusitis
Respiratory tract infections caused
Otitis media
Skin and skin-structure infections.
Bone infections
Genitourinary tract infections,
Dental infections.
A350455 - T10-435